You are here: Industry Insights > Ampligen

News List

AIM ImmunoTech reports no serious events from intranasal Covid-19 drug trial pharmaceutical-technology
April 09, 2021
AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Ampligen as an intranasal therapy for Covid-19.
AIM ImmunoTech Begins Dosing for Intranasal Ampligen Clinical Study americanpharmaceuticalreview
March 15, 2021
AIM ImmunoTech has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen as a potential intranasal therapy. AIM’s ‘s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage ...
AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study pharmaceutical-technology
March 10, 2021
AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.